MovDisordV3, Main, Exploration, bibRecord, 001A49

Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view

Identifieur interne : 001A49 ( Main/Exploration ); précédent : 001A48; suivant : 001A50

Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view

Auteurs : Cory Toth [Canada] ; Oksana Suchowersky [Canada] ; Douglas Zochodne [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2010-03-15.

RBID : ISTEX:C985418AFE9FAE2FB34C9648F232F1C5B3891A0E

English descriptors

KwdEn :
- Antiparkinson Agents (adverse effects), Humans, Levodopa (adverse effects), Parkinson Disease (drug therapy), Peripheral Nervous System Diseases (chemically induced), Peripheral Nervous System Diseases (prevention & control).
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemically induced : Peripheral Nervous System Diseases.
- drug therapy : Parkinson Disease.
- prevention & control : Peripheral Nervous System Diseases.
- Humans.

Url:

https://api.istex.fr/document/C985418AFE9FAE2FB34C9648F232F1C5B3891A0E/fulltext/pdf

DOI: 10.1002/mds.22879

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view</title>
<author><name sortKey="Toth, Cory" sort="Toth, Cory" uniqKey="Toth C" first="Cory" last="Toth">Cory Toth</name>
</author>
<author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name>
</author>
<author><name sortKey="Zochodne, Douglas" sort="Zochodne, Douglas" uniqKey="Zochodne D" first="Douglas" last="Zochodne">Douglas Zochodne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C985418AFE9FAE2FB34C9648F232F1C5B3891A0E</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22879</idno>
<idno type="url">https://api.istex.fr/document/C985418AFE9FAE2FB34C9648F232F1C5B3891A0E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003571</idno>
<idno type="wicri:Area/Istex/Curation">003571</idno>
<idno type="wicri:Area/Istex/Checkpoint">000728</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Toth C:reply:neuropathy:as</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20155864</idno>
<idno type="wicri:Area/PubMed/Corpus">001968</idno>
<idno type="wicri:Area/PubMed/Curation">001968</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001647</idno>
<idno type="wicri:Area/Ncbi/Merge">002A34</idno>
<idno type="wicri:Area/Ncbi/Curation">002A34</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002A34</idno>
<idno type="wicri:Area/Main/Merge">001E85</idno>
<idno type="wicri:Area/Main/Curation">001A49</idno>
<idno type="wicri:Area/Main/Exploration">001A49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view</title>
<author><name sortKey="Toth, Cory" sort="Toth, Cory" uniqKey="Toth C" first="Cory" last="Toth">Cory Toth</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurosciences, The Hotchkiss Brain Institute, and the University of Calgary, Calgary, Alberta</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurosciences, The Hotchkiss Brain Institute, and the University of Calgary, Calgary, Alberta</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zochodne, Douglas" sort="Zochodne, Douglas" uniqKey="Zochodne D" first="Douglas" last="Zochodne">Douglas Zochodne</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurosciences, The Hotchkiss Brain Institute, and the University of Calgary, Calgary, Alberta</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-03-15">2010-03-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="525">525</biblScope>
<biblScope unit="page" to="525">525</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C985418AFE9FAE2FB34C9648F232F1C5B3891A0E</idno>
<idno type="DOI">10.1002/mds.22879</idno>
<idno type="ArticleID">MDS22879</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Peripheral Nervous System Diseases (chemically induced)</term>
<term>Peripheral Nervous System Diseases (prevention & control)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Peripheral Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Peripheral Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Alberta</li>
</region>
<settlement><li>Calgary</li>
</settlement>
<orgName><li>Université de Calgary</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Alberta"><name sortKey="Toth, Cory" sort="Toth, Cory" uniqKey="Toth C" first="Cory" last="Toth">Cory Toth</name>
</region>
<name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name>
<name sortKey="Zochodne, Douglas" sort="Zochodne, Douglas" uniqKey="Zochodne D" first="Douglas" last="Zochodne">Douglas Zochodne</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A49 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A49 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:C985418AFE9FAE2FB34C9648F232F1C5B3891A0E
   |texte=   Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view

Reply: Neuropathy as a potential complication of levodopa use in Parkinson's disease: A pharmacological and pharmacovigilance point of view

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.